一种三价杆状病毒表达的流感病毒血凝素疫苗在老年人中的剂量相关安全性和免疫原性。
Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.
作者信息
Treanor John J, Schiff Gilbert M, Couch Robert B, Cate Thomas R, Brady Rebecca C, Hay C Mhorag, Wolff Mark, She Dewei, Cox Manon M J
机构信息
Infectious Disease Division, University of Rochester, Rochester, New York 14642, USA.
出版信息
J Infect Dis. 2006 May 1;193(9):1223-8. doi: 10.1086/503050. Epub 2006 Mar 28.
BACKGROUND
Influenza-virus hemagglutinin (HA) protein expressed in insect cells by recombinant baculovirus is a candidate influenza vaccine.
METHODS
In a randomized, double-blind trial conducted in 399 adults > or = 65 years of age, the efficacy of trivalent inactivated influenza vaccine (TIV) licensed for intramuscular injection was compared with that of trivalent baculovirus-expressed HA vaccine administered at doses of 15 microg, 45 microg, or 135 microg of each HA.
RESULTS
Compared with TIV, baculovirus-expressed HA vaccine was safe and induced better serum antibody responses to the H3 component when administered at doses of 45 microg or 135 microg of each HA.
CONCLUSIONS
Baculovirus-expressed HA is a safe and immunogenic influenza vaccine in elderly adults.
背景
通过重组杆状病毒在昆虫细胞中表达的流感病毒血凝素（HA）蛋白是一种候选流感疫苗。
方法
在一项针对399名年龄≥65岁成年人的随机双盲试验中，将许可用于肌肉注射的三价灭活流感疫苗（TIV）与以每HA 15微克、45微克或135微克剂量给药的三价杆状病毒表达的HA疫苗的效力进行了比较。
结果
与TIV相比，杆状病毒表达的HA疫苗在以每HA 45微克或135微克剂量给药时是安全的，并且对H3成分诱导了更好的血清抗体反应。
结论
杆状病毒表达的HA在老年人中是一种安全且具有免疫原性的流感疫苗。
Zotero 插件